216 related articles for article (PubMed ID: 18287563)
1. The death ligand TRAIL in diabetic nephropathy.
Lorz C; Benito-Martín A; Boucherot A; Ucero AC; Rastaldi MP; Henger A; Armelloni S; Santamaría B; Berthier CC; Kretzler M; Egido J; Ortiz A
J Am Soc Nephrol; 2008 May; 19(5):904-14. PubMed ID: 18287563
[TBL] [Abstract][Full Text] [Related]
2. The osteoprotegerin/tumor necrosis factor related apoptosis-inducing ligand axis in the kidney.
Candido R
Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):69-74. PubMed ID: 24247823
[TBL] [Abstract][Full Text] [Related]
3. PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation.
Tanaka H; Hoshikawa Y; Oh-hara T; Koike S; Naito M; Noda T; Arai H; Tsuruo T; Fujita N
Mol Cancer Res; 2009 Apr; 7(4):557-69. PubMed ID: 19372584
[TBL] [Abstract][Full Text] [Related]
4. Trail and kidney disease.
Lorz C; Benito A; Ucero AC; Santamaría B; Ortiz A
Front Biosci (Landmark Ed); 2009 Jan; 14(10):3740-9. PubMed ID: 19273307
[TBL] [Abstract][Full Text] [Related]
5. [Effects of valsartan, mycophenolate mofetil and their combined application on TRAIL and nuclear factor-kappaB expression in the kidneys of diabetic rats].
Chen B; Zhang Y; Liu G; Guan GJ; Hou XH; Li XG; Liu JL
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(8):540-5. PubMed ID: 18649770
[TBL] [Abstract][Full Text] [Related]
6. Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells.
Shlyakhtina Y; Pavet V; Gronemeyer H
Cell Death Dis; 2017 Aug; 8(8):e3025. PubMed ID: 29048428
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines.
Shetty S; Gladden JB; Henson ES; Hu X; Villanueva J; Haney N; Gibson SB
Apoptosis; 2002 Oct; 7(5):413-20. PubMed ID: 12207174
[TBL] [Abstract][Full Text] [Related]
8. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
9. Tumour necrosis factor-related apoptosis-inducing ligand expression in patients with diabetic nephropathy.
Chang WW; Liang W; Yao XM; Zhang L; Zhu LJ; Yan C; Jin YL; Yao YS
J Renin Angiotensin Aldosterone Syst; 2018; 19(3):1470320318785744. PubMed ID: 29999450
[TBL] [Abstract][Full Text] [Related]
10. TRAIL, DR4 and DR5 are upregulated in kidneys from patients with lupus nephritis and exert proliferative and proinflammatory effects.
Nguyen V; Cudrici C; Zernetkina V; Niculescu F; Rus H; Drachenberg C; Rus V
Clin Immunol; 2009 Jul; 132(1):32-42. PubMed ID: 19349211
[TBL] [Abstract][Full Text] [Related]
11. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways.
Vitovski S; Phillips JS; Sayers J; Croucher PI
J Biol Chem; 2007 Oct; 282(43):31601-9. PubMed ID: 17702740
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of TRAIL and its receptors on peripheral T-cells in type 1 diabetic patients.
Salehi E; Vodjgani M; Massoud A; Keyhani A; Rajab A; Shafaghi B; Gheflati Z; Aboufazeli T
Iran J Immunol; 2007 Dec; 4(4):197-205. PubMed ID: 18057577
[TBL] [Abstract][Full Text] [Related]
13. Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression.
Vigneswaran N; Baucum DC; Wu J; Lou Y; Bouquot J; Muller S; Zacharias W
BMC Cancer; 2007 Jun; 7():108. PubMed ID: 17592646
[TBL] [Abstract][Full Text] [Related]
14. [Transcriptomics illustrate a deadly TRAIL to diabetic nephropathy].
Benito-Martín A; Ucero AC; Santamaría B; Lorz C; Kretzler M; Rastaldi MP; Sánchez-Niño MD; Sanz A; Izquierdo MC; Ruiz Ortega M; Egido J; Ortiz A
Nefrologia; 2009; 29(1):13-9. PubMed ID: 19240767
[TBL] [Abstract][Full Text] [Related]
15. TRAIL treatment prevents renal morphological changes and TGF-β-induced mesenchymal transition associated with diabetic nephropathy.
Toffoli B; Tonon F; Tisato V; Michelli A; Zauli G; Secchiero P; Fabris B; Bernardi S
Clin Sci (Lond); 2020 Sep; 134(17):2337-2352. PubMed ID: 32857135
[TBL] [Abstract][Full Text] [Related]
16. Regulation of TNF-related apoptosis-inducing ligand-mediated death-signal pathway in human beta cells by Fas-associated death domain and nuclear factor kappaB.
Ou D; Wang X; Metzger DL; Robbins M; Huang J; Jobin C; Chantler JK; James RF; Pozzilli P; Tingle AJ
Hum Immunol; 2005 Jul; 66(7):799-809. PubMed ID: 16112027
[TBL] [Abstract][Full Text] [Related]
17. TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cells.
Kim YS; Schwabe RF; Qian T; Lemasters JJ; Brenner DA
Hepatology; 2002 Dec; 36(6):1498-508. PubMed ID: 12447876
[TBL] [Abstract][Full Text] [Related]
18. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
Yang J; Li G; Zhang K
Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-140-5p ameliorates the high glucose-induced apoptosis and inflammation through suppressing TLR4/NF-κB signaling pathway in human renal tubular epithelial cells.
Su J; Ren J; Chen H; Liu B
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32073611
[TBL] [Abstract][Full Text] [Related]
20. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy.
Mezzano S; Aros C; Droguett A; Burgos ME; Ardiles L; Flores C; Schneider H; Ruiz-Ortega M; Egido J
Nephrol Dial Transplant; 2004 Oct; 19(10):2505-12. PubMed ID: 15280531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
